GlassScriptPhysician profile
Jeffrey Short
NPI 1770568503
$6,698.27
in general payments reported to CMS, 2019-2025
38 companies · $1,923 in 2025
The $1,923 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,075 · 2022: $487 · 2023: $674 · 2024: $1,539 · 2025: $1,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,136.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $977.25 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $830.03 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $574.65 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $466.52 | 2024-2025 | Voquezna |
| Amgen INC. | $449.91 | 2021-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $437.91 | 2021-2025 | Verquvo, Belsomra, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.76 | 2021-2025 | Ofev, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $342.47 | 2022-2025 | |
| Lilly USA, LLC | $278.32 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Daiichi Sankyo INC. | $214.81 | 2021-2024 | Injectafer |
| Glaxosmithkline, LLC. | $193.26 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $148.56 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $146.86 | 2021-2022 | |
| Insulet Corporation | $141.24 | 2025 | Omnipod, Omnipod |
| Esperion Therapeutics, INC. | $114.31 | 2021-2023 | Nexletol |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Short listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.